Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

ANTXAN2 Therapeutics, Inc.

Nasdaq · CIK 0001880438
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts184

Identity from submissions API

NameAN2 Therapeutics, Inc.
CIK0001880438
TickersANTX
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SIC2834 Pharmaceutical Preparations
EIN820606654
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone(650) 331-9090
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
1300 EL CAMINO REAL, SUITE 100
MENLO PARK
CA
94025
CA
Mailing address
1300 EL CAMINO REAL, SUITE 100
MENLO PARK
CA
94025
CA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

390 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001831942-26-000048 005-93617 261560394 34 15656
2026-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-127408 005-93617 261554940 34 18905
2026-11-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-461157 005-93617 261554454 34 6885
2026-11-09 10-Q 10-Q 0001193125-26-452664 001-41331 261533828 34 9929168 1 1
2026-11-09 8-K 8-K 2.02,9.01 0001193125-26-452660 001-41331 261533824 34 372451 1 1
2026-11-06 4 4 0001193125-26-452184 5703
2026-10-13 4 4 0001193125-26-420643 4694
2026-10-13 4 4 0001193125-26-420641 4702
2026-10-13 4 4 0001193125-26-420639 7436
2026-09-16 4 4 0001193125-26-393274 7429
2026-09-14 S-8 S-8 0001880438-26-000002 333-298920 261377395 33 806746 1 1
2026-09-11 4 4 0001193125-26-389545 8696
2026-09-08 4 4 0001193125-26-385511 12010
2026-09-04 4 4 0001193125-26-383697 5827
2026-09-02 4 4 0001193125-26-380595 4507
2026-08-27 3 3 0001193125-26-370943 3152
2026-08-19 4 4 0001193125-26-357225 8700
2026-08-17 144 xsl144X01/primary_doc.xml 0001972481-26-000263 001-41331 261286962 33 6133
2026-08-14 4 4 0001193125-26-351801 5563
2026-08-11 10-Q 10-Q 0001193125-26-344569 001-41331 261263092 34 9264793 1 1
2026-08-11 8-K 8-K 2.02,9.01 0001193125-26-344549 001-41331 261263051 34 364570 1 1
2026-07-10 4 4 0001193125-26-301167 7436
2026-07-10 4 4 0001193125-26-301166 4694
2026-07-10 4 4 0001193125-26-301165 4702
2026-07-10 4 4 0001193125-26-301092 5696
2026-06-09 8-K 8-K 5.07 0001193125-26-262264 001-41331 261073917 34 164225 1 1
2026-06-04 8-K 8-K 7.01,8.01,9.01 0001193125-26-257430 001-41331 261065182 34 191613 1 1
2026-06-02 4 4 0001193125-26-253622 5824
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002073679-26-000066 005-93617 26990604 34 6532
2026-05-11 10-Q 10-Q 0001193125-26-216755 001-41331 26963222 34 8127142 1 1
2026-05-11 8-K 8-K 2.02,9.01 0001193125-26-216752 001-41331 26963162 34 310292 1 1
2026-04-22 ARS ARS 0001193125-26-170328 001-41331 26883670 34 796433
2026-04-22 DEFA14A DEFA14A 0001193125-26-170321 001-41331 26883657 34 221872
2026-04-22 DEF 14A DEF 14A 0001193125-26-170314 001-41331 26883643 34 1876391 1 1
2026-04-20 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-001256 333-294956 26876626 33 1733
2026-04-20 424B3 424B3 0001193125-26-164101 333-294956 26875472 33 494498
2026-04-20 424B5 424B5 0001193125-26-164095 333-294956 26875455 33 488209
2026-04-16 CORRESP filename1.htm 0001193125-26-158794 7193
2026-04-15 UPLOAD filename1.pdf 0000000000-26-003830 333-294956 40036
2026-04-10 4 4 0001193125-26-151632 7436
2026-04-10 4 4 0001193125-26-151628 4694
2026-04-10 4 4 0001193125-26-151626 4703
2026-04-09 S-3 S-3 0001193125-26-149869 333-294956 26852575 33 1175090 1 1
2026-04-09 8-K 8-K 8.01,9.01 0001193125-26-149822 001-41331 26852407 34 400725 1 1
2026-03-25 D xslFormDX01/primary_doc.xml 06b 0001880438-26-000001 021-577698 26793048 33 21142
2026-03-23 4 4 0001193125-26-120236 16750
2026-03-23 4 4 0001193125-26-120235 16796
2026-03-23 4 4 0001193125-26-120230 16208
2026-03-23 4 4 0001193125-26-120226 12185
2026-03-23 4 4 0001193125-26-120223 16217
2026-03-23 4 4 0001193125-26-120221 16276
2026-03-23 4 4 0001193125-26-120216 16210
2026-03-23 4 4 0001193125-26-120214 16213
2026-03-23 4 4 0001193125-26-120210 12797
2026-03-23 4 4 0001193125-26-120207 16207
2026-03-23 4 4 0001193125-26-120200 12159
2026-03-23 4 4 0001193125-26-120192 16796
2026-03-20 8-K 8-K 5.02 0001193125-26-117765 001-41331 26778728 34 142893 1 1
2026-03-17 S-8 S-8 0001193125-26-110791 333-294375 26761960 33 521965 1 1
2026-03-17 10-K 10-K 0001193125-26-110693 001-41331 26761684 34 10409377 1 1
2026-03-17 8-K 8-K 2.02,9.01 0001193125-26-110681 001-41331 26761655 34 372214 1 1
2026-03-16 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001831942-26-000014 005-93617 26757048 34 15839
2026-03-13 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-26-027730 005-93617 26753342 34 19778
2026-03-13 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001213900-26-027660 005-93617 26752331 34 19809
2026-03-10 8-K 8-K 1.01,3.02,7.01,9.01 0001193125-26-099169 001-41331 26737019 34 632118 1 1
2026-03-05 4 4 0001193125-26-094490 5725
2026-02-23 4 4 0001193125-26-064176 8004
2026-02-23 4 4 0001193125-26-064174 7711
2026-02-23 4 4 0001193125-26-064166 18687
2026-02-23 4 4 0001193125-26-064151 10030
2026-02-23 4 4 0001193125-26-064141 7699
2026-02-23 4 4 0001193125-26-064105 5143
2026-02-23 4 4 0001193125-26-064103 5163
2026-02-23 4 4 0001193125-26-064089 5145
2026-02-23 4 4 0001193125-26-064069 5152
2026-02-23 4 4 0001193125-26-064061 5142
2026-02-23 4 4 0001193125-26-064059 5131
2026-02-23 4 4 0001193125-26-064028 5211
2026-02-23 4 4 0001193125-26-063984 5148
2026-02-17 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001596468-26-000004 005-93617 26644472 34 6470
2026-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001193125-26-051535 005-93617 26633530 34 6901
2026-02-03 3 3 0001193125-26-036046 7648
2026-01-29 8-K 8-K 5.02 0001193125-26-029540 001-41331 26578848 34 145354 1 1
2026-01-14 4 4 0001193125-26-013041 7300
2026-01-14 4 4 0001193125-26-013038 4566
2026-01-14 4 4 0001193125-26-013035 4558
2026-01-07 4 4 0001193125-26-006771 6817
2026-01-07 4 4 0001193125-26-006770 6960
2026-01-07 4 4 0001193125-26-006765 6863
2026-01-07 4 4 0001193125-26-006763 7310
2025-11-14 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001596468-25-000022 005-93617 251488955 34 6465
2025-11-12 10-Q 10-Q 0001193125-25-277673 001-41331 251473118 34 8771361 1 1
2025-11-12 8-K 8-K 2.02,9.01 0001193125-25-277662 001-41331 251473081 34 386983 1 1
2025-11-06 4 4 0001193125-25-270255 5492
2025-11-06 4 4 0001193125-25-270252 5432
2025-10-14 4 4 0001193125-25-238984 4555
2025-10-14 4 4 0001193125-25-238983 7297
2025-10-14 4 4 0001193125-25-238982 4563
2025-08-12 10-Q 10-Q 0000950170-25-107301 001-41331 251206655 34 8353682 1 1
2025-08-12 8-K 8-K 9.01 0000950170-25-107278 001-41331 251206528 34 347871 1 1
2025-07-11 4 4 0000950170-25-095408 7295
2025-07-11 4 4 0000950170-25-095406 4552
2025-07-11 4 4 0000950170-25-095403 4560
2025-06-20 8-K 8-K 3.02,9.01 0001193125-25-143187 001-41331 251059052 34 257724 1 1
2025-06-18 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001373604-25-000092 005-93617 251055520 34 8997
2025-06-16 4 xslF345X05/form4.xml 0001373604-25-000090 5002
2025-06-11 8-K 8-K 7.01,9.01 0001193125-25-138796 001-41331 251038777 34 16245233 1 1
2025-06-04 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000935836-25-000414 005-93617 251024283 34 20565
2025-06-03 4 4 0000950170-25-081041 7963
2025-05-30 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0001373604-25-000086 005-93617 251012500 34 9038
2025-05-30 4 xslF345X05/form4.xml 0001373604-25-000084 9774
2025-05-29 4 4 0000950170-25-078982 4885
2025-05-27 8-K 8-K 5.07 0001193125-25-127595 001-41331 25989026 34 149674 1 1
2025-05-23 4 4 0000950170-25-077073 5154
2025-05-23 4 4 0000950170-25-077070 5143
2025-05-23 4 4 0000950170-25-077062 5202
2025-05-23 4 4 0000950170-25-077061 5139
2025-05-23 4 4 0000950170-25-077058 5168
2025-05-23 4 4 0000950170-25-077053 5141
2025-05-23 4 4 0000950170-25-077036 5134
2025-05-23 4 4 0000950170-25-077035 5121
2025-05-13 10-Q 10-Q 0000950170-25-070358 001-41331 25940236 34 7677963 1 1
2025-05-13 8-K 8-K 9.01 0000950170-25-070305 001-41331 25939950 34 308437 1 1
2025-05-07 SCHEDULE 13D xslSCHEDULE_13D_X01/primary_doc.xml 0001373604-25-000074 005-93617 25919814 34 13120
2025-05-01 8-K 8-K 7.01,9.01 0001193125-25-110019 001-41331 25903676 34 179076 1 1
2025-04-11 4 4 0000950170-25-053373 5407
2025-04-11 4 4 0000950170-25-053367 7292
2025-04-11 4 4 0000950170-25-053355 4559
2025-04-11 4 4 0000950170-25-053348 4551
2025-04-11 ARS ARS 0000950170-25-052971 001-41331 25829450 34 2236894
2025-04-10 DEFA14A DEFA14A 0000950170-25-052853 001-41331 25828482 34 1129931
2025-04-10 DEF 14A DEF 14A 0000950170-25-052852 001-41331 25828367 34 3686196 1 1
2025-03-25 S-8 S-8 0000950170-25-044432 333-286094 25768688 33 530812 1 1
2025-03-25 10-K 10-K 0000950170-25-044366 001-41331 25768334 34 10696094 1 1
2025-03-25 8-K 8-K 2.02,9.01 0000950170-25-044353 001-41331 25768239 34 345953 1 1
2025-02-28 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-030289 005-93617 25693139 34 114829
2025-02-28 4 4 0000950170-25-030057 7391
2025-02-28 4 4 0000950170-25-030052 7292
2025-02-28 4 4 0000950170-25-030042 7544
2025-02-28 4 4 0000950170-25-030041 9838
2025-02-28 4 4 0000950170-25-030032 7483
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-004263 005-93617 25631674 34 17069
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-021346 005-93617 25630152 34 113542
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-014185 005-93617 25629635 34 6591
2025-02-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001415889-25-003979 005-93617 25624934 34 37514
2025-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-019942 005-93617 25620748 34 7084
2025-02-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001373604-25-000020 005-93617 25620714 34 6445
2025-01-07 4 4 0000950170-25-003160 5195
2025-01-07 4 4 0000950170-25-003157 5387
2025-01-07 4 4 0000950170-25-003153 5166
2025-01-07 4 4 0000950170-25-003152 5224
2024-12-23 4 4 0000950170-24-139804 4571
2024-12-23 4 4 0000950170-24-139800 7304
2024-12-23 4 4 0000950170-24-139797 4563
2024-12-23 4 4 0000950170-24-139793 5414
2024-12-23 4 4 0000950170-24-139792 7057
2024-12-10 4 4 0000950170-24-135150 16286
2024-11-27 4 4 0000950170-24-131660 12169
2024-11-27 4 4 0000950170-24-131499 5191
2024-11-21 4 4 0000950170-24-129830 11176
2024-11-20 4 4 0000950170-24-129248 6562
2024-11-18 4 4 0000950170-24-128202 7277
2024-11-14 SC 13G/A AMENDMENT NO. 2 TO SCHEDULE 13G 0000921895-24-002722 005-93617 241463058 34 266497
2024-11-14 SC 13G/A SC 13G/A 0001104659-24-118948 005-93617 241462611 34 136477
2024-11-13 SC 13G/A SC 13G/A 0001193125-24-257248 005-93617 241454725 34 60735
2024-11-13 10-Q 10-Q 0000950170-24-126282 001-41331 241453931 34 7473293 1 1
2024-11-13 8-K 8-K 2.02,9.01 0000950170-24-126276 001-41331 241453886 34 329092 1 1
2024-11-05 4 4 0000950170-24-121601 7697
2024-11-05 4 4 0000950170-24-121591 7958
2024-11-05 3 3 0000950170-24-121585 20591
2024-11-05 8-K 8-K 5.02 0001193125-24-251240 001-41331 241427428 34 149159 1 1
2024-08-28 SC 13G/A AMENDMENT NO. 1 0001214659-24-015449 005-93617 241255364 34 68441
2024-08-19 8-A12B 8-A12B 0001193125-24-202437 001-41331 241218191 34 31540
2024-08-19 8-K 8-K 1.01,3.03,5.03,9.01 0001193125-24-202430 001-41331 241218175 34 617980 1 1
2024-08-15 144 xsl144X01/primary_doc.xml 0001178937-24-000045 001-41331 241213569 33 4541
2024-08-15 144 xsl144X01/primary_doc.xml 0001178937-24-000044 001-41331 241213548 33 4412
2024-08-14 SC 13G/A antx13g.htm 0001373604-24-000073 005-93617 241210371 34 56828
2024-08-14 4 xslF345X05/form4.xml 0001373604-24-000066 4953
2024-08-13 SC 13G/A SC 13G/A 0001104659-24-089067 005-93617 241203235 34 85517
2024-08-13 4 xslF345X05/form4-08132024_090830.xml 0001415889-24-021199 14610
2024-08-13 10-Q 10-Q 0000950170-24-096243 001-41331 241201675 34 7210938 1 1
2024-08-13 8-K 8-K 2.02,9.01 0000950170-24-096173 001-41331 241201397 34 287385 1 1
2024-08-12 3 xslF345X02/form3.xml 0001373604-24-000064 4166
2024-08-12 SC 13G antx13g.htm 0001373604-24-000062 005-93617 241197553 34 56840
2024-08-08 8-K 8-K 2.05,5.02,7.01,8.01,9.01 0001193125-24-197047 001-41331 241189268 34 175722 1 1
2024-07-12 4 4 0000950170-24-083200 17663
2024-07-03 SC 13G x72241sc13g.htm 0001214659-24-011905 005-93617 241098276 34 68465
2024-06-24 8-K 8-K 5.07,9.01 0001193125-24-166938 001-41331 241064290 34 199360 1 1
2024-06-21 4 4 0000950170-24-076410 17479
2024-06-21 4 4 0000950170-24-076408 17909
2024-06-21 4 4 0000950170-24-076406 17981
2024-06-21 4 4 0000950170-24-076404 18447
2024-06-21 4 4 0000950170-24-076399 18470
2024-06-21 4 4 0000950170-24-076374 17943
2024-06-21 4 4 0000950170-24-076369 17918
2024-06-21 4 4 0000950170-24-076361 18433
2024-05-14 10-Q 10-Q 0000950170-24-059556 001-41331 24944475 34 6751349 1 1
2024-05-14 8-K 8-K 2.02,9.01 0000950170-24-059527 001-41331 24944305 34 256869 1 1
2024-05-14 10-K/A 10-K/A 0000950170-24-059488 001-41331 24944081 34 1621637 1 1
2024-04-26 ARS ARS 0000950170-24-049195 001-41331 24884214 34 2485062
2024-04-26 DEFA14A DEFA14A 0000950170-24-049172 001-41331 24884085 34 1824369
2024-04-26 DEF 14A DEF 14A 0000950170-24-049148 001-41331 24883944 34 4091893
2024-04-10 SC 13G SC 13G 0001193125-24-091977 005-93617 24836351 34 326832
2024-04-05 PRE 14A PRE 14A 0000950170-24-042271 001-41331 24826658 34 1142279
2024-03-29 S-8 S-8 0000950170-24-038752 333-278399 24804749 33 219914
2024-03-29 10-K 10-K 0000950170-24-038681 001-41331 24804379 34 9448568 1 1
2024-03-29 4/A xslF345X05/form4.xml 0001610717-24-000196 4662
2024-03-29 4/A xslF345X05/form4.xml 0001610717-24-000195 4618
2024-03-29 4/A xslF345X05/form4.xml 0001610717-24-000194 4662
2024-03-29 4/A xslF345X05/form4.xml 0001610717-24-000193 16037
2024-03-29 4/A xslF345X05/form4.xml 0001610717-24-000192 4714
2024-03-29 4/A xslF345X05/form4.xml 0001610717-24-000191 24750
2024-03-28 8-K 8-K 2.02,9.01 0000950170-24-038055 001-41331 24799131 34 307628 1 1
2024-03-18 4 xslF345X05/form4.xml 0001610717-24-000169 6970
2024-03-18 4 xslF345X05/form4.xml 0001610717-24-000168 7255
2024-03-18 4 xslF345X05/form4.xml 0001610717-24-000167 18152
2024-03-18 4 xslF345X05/form4.xml 0001610717-24-000166 7068
2024-03-18 4 xslF345X05/form4.xml 0001610717-24-000165 7008
2024-03-18 4 xslF345X05/form4.xml 0001610717-24-000164 29458
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023990 005-93617 24640171 34 88755
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023929 005-93617 24639966 34 137732
2024-02-14 SC 13G/A SC 13G A AN2 0000078003-24-000031 005-93617 24636140 34 52370
2024-02-13 SC 13G SC 13G 0001193125-24-033944 005-93617 24629179 34 41160
2024-02-12 SC 13G/A JHG PLC AND JHBIF OWN <5% 0001274173-24-000020 005-93617 24619066 34 12626
2024-02-12 8-K 8-K 8.01 0001193125-24-031008 001-41331 24617335 34 158074 1 1
2024-02-09 SC 13G/A SC 13G/A 0001193125-24-030111 005-93617 24615465 34 57382
2024-02-09 SC 13G/A SC 13G/A 0001193125-24-029181 005-93617 24611132 34 91124
2024-01-19 4 4 0000950170-24-005900 17166
2024-01-18 4 4 0000950170-24-005515 7346
2024-01-18 4 4 0000950170-24-005513 13083
2024-01-18 144 xsl144X01/primary_doc.xml 0001950047-24-000370 001-41331 24542363 33 4693
2024-01-17 4 FORM 4 SUBMISSION 0001209191-24-001770 8886
2024-01-16 144 xsl144X01/primary_doc.xml 0001961863-24-000003 001-41331 24536164 33 5874
2024-01-16 144 xsl144X01/primary_doc.xml 0001961863-24-000002 001-41331 24536142 33 5869
2024-01-12 4 FORM 4 SUBMISSION 0001209191-24-001537 13278
2024-01-11 4 xslF345X05/form4.xml 0001610717-24-000027 12372
2024-01-10 144 xsl144X01/primary_doc.xml 0001950047-24-000261 001-41331 24526732 33 5064
2024-01-10 144 xsl144X01/primary_doc.xml 0001950047-24-000260 001-41331 24526731 33 5071
2024-01-04 4 xslF345X05/form4.xml 0001610717-24-000014 20484
2024-01-04 4 xslF345X05/form4.xml 0001610717-24-000013 27121
2024-01-02 144 xsl144X01/primary_doc.xml 0001950047-24-000081 001-41331 24503136 33 4685
2024-01-02 144 xsl144X01/primary_doc.xml 0001950047-24-000053 001-41331 24503008 33 4720
2023-11-16 4 4 0000950170-23-064611 13584
2023-11-16 4 4 0000950170-23-064609 7997
2023-11-14 144 xsl144X01/primary_doc.xml 0001950047-23-004936 001-41331 231406331 33 11138
2023-11-09 10-Q 10-Q 0000950170-23-062081 001-41331 231392645 34 8468383 1 1
2023-11-09 8-K 8-K 2.02,9.01 0000950170-23-062046 001-41331 231392463 34 362892 1 1
2023-10-03 4 4 0000950170-23-051733 11726
2023-10-03 4 4 0000950170-23-051728 17155
2023-10-02 144 xsl144X01/primary_doc.xml 0001950047-23-004323 001-41331 231299731 33 10360
2023-09-29 4 4 0000950170-23-050853 17150
2023-09-29 4 4 0000950170-23-050851 11723
2023-09-29 144 xsl144X01/primary_doc.xml 0001950047-23-004305 001-41331 231295648 33 9583
2023-09-15 4 4 0000950170-23-048436 7475
2023-09-15 4 4 0000950170-23-048422 13066
2023-09-13 8-K 8-K 8.01,9.01 0001193125-23-233934 001-41331 231251634 34 164832 1 1
2023-09-08 4 4 0000950170-23-047312 17154
2023-09-08 4 4 0000950170-23-047311 11723
2023-09-08 8-K 8-K 5.02 0001193125-23-230786 001-41331 231243185 34 146189 1 1
2023-08-25 4 4 0000950170-23-044594 12838
2023-08-25 4 4 0000950170-23-044593 7259
2023-08-23 144 xsl144X01/primary_doc.xml 0001950047-23-003395 001-41331 231197741 33 4917
2023-08-22 4 OWNERSHIP DOCUMENT 0001104659-23-094274 13350
2023-08-16 424B5 424B5 0001193125-23-214364 333-271174 231178788 33 437254
2023-08-16 8-K 8-K 1.01,8.01,9.01 0001193125-23-214362 001-41331 231178756 34 467936 1 1
2023-08-10 10-Q 10-Q 0000950170-23-041378 001-41331 231159938 34 8478091 1 1
2023-08-10 8-K 8-K 2.02,9.01 0000950170-23-041358 001-41331 231159757 34 387321 1 1
2023-07-25 SC 13G SC 13G 0001193125-23-193456 005-93617 231108778 34 76145
2023-07-05 SC 13G BIOTECH (NON-RIC) OWNS 5% 0001274173-23-000083 005-93617 231070119 34 12822
2023-06-09 4 FORM 4 SUBMISSION 0000899243-23-015326 9103
2023-06-09 4 FORM 4 SUBMISSION 0000899243-23-015321 9132
2023-06-09 4 FORM 4 SUBMISSION 0000899243-23-015320 9198
2023-06-09 4 FORM 4 SUBMISSION 0000899243-23-015317 9128
2023-06-09 4 FORM 4 SUBMISSION 0000899243-23-015314 9129
2023-06-09 4 FORM 4 SUBMISSION 0000899243-23-015313 9132
2023-06-09 4 FORM 4 SUBMISSION 0000899243-23-015310 9158
2023-06-09 4 FORM 4 SUBMISSION 0000899243-23-015307 5447
2023-06-09 8-K 8-K 5.07 0001193125-23-164459 001-41331 231005406 34 157793 1 1
2023-05-15 4 FORM 4 SUBMISSION 0000899243-23-013012 10751
2023-05-11 10-Q 10-Q 0000950170-23-021291 001-41331 23911395 34 7898608 1 1
2023-05-11 8-K 8-K 2.02,9.01 0000950170-23-021275 001-41331 23911325 34 336485 1 1
2023-04-26 ARS ARS 0000950170-23-014842 001-41331 23850119 34 9418197
2023-04-26 DEFA14A DEFA14A 0000950170-23-014813 001-41331 23849921 34 1146488
2023-04-26 DEF 14A DEF 14A 0000950170-23-014794 001-41331 23849748 34 2816305
2023-04-14 424B5 424B5 0001193125-23-100832 333-271174 23819469 33 459776
2023-04-13 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-04-13 16:00:00 9999999995-23-000930 333-271174 23819590 33 1687
2023-04-11 CORRESP filename1.htm 0001193125-23-097786 7065
2023-04-10 UPLOAD filename1.pdf 0000000000-23-003544 40180
2023-04-06 S-3 S-3 0001193125-23-094152 333-271174 23807026 33 1393495
2023-03-30 S-8 S-8 0001193125-23-084122 333-270962 23776963 33 88779
2023-03-29 10-K 10-K 0000950170-23-010627 001-41331 23775551 34 11198030 1 1
2023-03-29 8-K 8-K 2.02,9.01 0000950170-23-010615 001-41331 23775413 34 424630 1 1
2023-02-24 4 FORM 4 SUBMISSION 0000899243-23-006150 5315
2023-02-17 4 FORM 4 SUBMISSION 0000899243-23-005558 5281
2023-02-17 4 FORM 4 SUBMISSION 0000899243-23-005557 5377
2023-02-17 4 FORM 4 SUBMISSION 0000899243-23-005555 5325
2023-02-17 4 FORM 4 SUBMISSION 0000899243-23-005554 5325
2023-02-17 4 FORM 4 SUBMISSION 0000899243-23-005550 5345
2023-02-17 4 FORM 4 SUBMISSION 0000899243-23-005545 5345
2023-02-14 SC 13G/A SC 13G/A 0001104659-23-021812 005-93617 23630735 34 77642
2023-02-14 SC 13G/A AMENDMENT NO. 1 TO THE SCHEDULE 13G 0000921895-23-000525 005-93617 23624975 34 277119
2023-02-14 SC 13G/A SC 13G/A 0001104659-23-020803 005-93617 23622814 34 140771
2023-02-13 SC 13G SC 13G AN2 THERAPEUTICS 0000078003-23-000011 005-93617 23619743 34 75379
2023-02-13 SC 13G SC 13G 0001104659-23-019766 005-93617 23619287 34 35554
2023-02-10 SC 13G SC 13G 0001193125-23-032801 005-93617 23613093 34 92596
2022-11-14 4 FORM 4 SUBMISSION 0000899243-22-035782 10349
2022-11-09 4 FORM 4 SUBMISSION 0000899243-22-035472 11498
2022-11-09 10-Q 10-Q 0000950170-22-023901 001-41331 221372985 34 9637447 1 1
2022-11-09 8-K 8-K 2.02,9.01 0000950170-22-023882 001-41331 221372889 34 363814 1 1
2022-11-07 4 FORM 4 SUBMISSION 0000899243-22-035311 14618
2022-11-02 4 FORM 4 SUBMISSION 0000899243-22-034840 9942
2022-10-28 4 FORM 4 SUBMISSION 0000899243-22-034497 9939
2022-10-28 4 FORM 4 SUBMISSION 0000899243-22-034442 5395
2022-10-26 4 FORM 4 SUBMISSION 0000899243-22-034294 13040
2022-10-24 4 FORM 4 SUBMISSION 0000899243-22-034092 13053
2022-10-06 8-K 8-K 7.01,9.01 0001193125-22-258534 001-41331 221297092 34 167531 1 1
2022-10-05 3 FORM 3 SUBMISSION 0000899243-22-033045 6608
2022-08-11 10-Q 10-Q 0000950170-22-016900 001-41331 221156232 34 8882338 1 1
2022-08-11 8-K 8-K 2.02,9.01 0000950170-22-016887 001-41331 221156131 34 350429 1 1
2022-08-05 4 OWNERSHIP DOCUMENT 0001104659-22-086686 14706
2022-07-28 4 OWNERSHIP DOCUMENT 0001104659-22-083728 14989
2022-06-29 8-K 8-K 8.01,9.01 0001193125-22-185058 001-41331 221054783 34 164288 1 1
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-024054 8013
2022-06-24 4 FORM 4 SUBMISSION 0000899243-22-024050 13552
2022-06-24 4/A FORM 4/A SUBMISSION 0000899243-22-024034 27665
2022-06-24 3/A FORM 3/A SUBMISSION 0000899243-22-024031 14987
2022-06-23 4 OWNERSHIP DOCUMENT 0001104659-22-073920 12870
2022-06-15 4 OWNERSHIP DOCUMENT 0001104659-22-071465 14751
2022-05-16 4 FORM 4 SUBMISSION 0000899243-22-018296 5376
2022-05-16 4 FORM 4 SUBMISSION 0000899243-22-018293 5292
2022-05-16 4 FORM 4 SUBMISSION 0000899243-22-018292 5324
2022-05-16 4 FORM 4 SUBMISSION 0000899243-22-018290 5281
2022-05-16 4 FORM 4 SUBMISSION 0000899243-22-018289 5279
2022-05-16 4 FORM 4 SUBMISSION 0000899243-22-018287 5344
2022-05-16 4 FORM 4 SUBMISSION 0000899243-22-018286 5334
2022-05-16 4 FORM 4 SUBMISSION 0000899243-22-018282 5260
2022-05-16 4 FORM 4 SUBMISSION 0000899243-22-018281 5305
2022-05-16 4 FORM 4 SUBMISSION 0000899243-22-018278 5344
2022-05-16 4 FORM 4 SUBMISSION 0000899243-22-018276 5280
2022-05-16 4 FORM 4 SUBMISSION 0000899243-22-018273 5277
2022-05-16 4 FORM 4 SUBMISSION 0000899243-22-018272 5272
2022-05-16 4 FORM 4 SUBMISSION 0000899243-22-018271 5314
2022-05-10 10-Q 10-Q 0000950170-22-008999 001-41331 22910076 34 7763143 1 1
2022-05-10 8-K 8-K 2.02,9.01 0000950170-22-008992 001-41331 22909902 34 346848 1 1
2022-05-09 4 FORM 4 SUBMISSION 0000899243-22-017371 5312
2022-05-09 3 FORM 3 SUBMISSION 0000899243-22-017369 6603
2022-05-09 8-K 8-K 5.02,9.01 0001193125-22-145000 001-41331 22905148 34 25002
2022-04-08 SC 13G AN2 THERAPEUTICS, INC. 0001104659-22-044249 005-93617 22817440 34 77451
2022-04-08 SC 13G AN2 THERAPEUTICS, INC. 0001104659-22-044208 005-93617 22817115 34 133481
2022-04-04 SC 13G THE SCHEDULE 13G 0000921895-22-001065 005-93617 22802937 34 285810
2022-03-31 4 FORM 4 SUBMISSION 0000899243-22-012992 6991
2022-03-31 4 FORM 4 SUBMISSION 0000899243-22-012991 24171
2022-03-31 4 FORM 4 SUBMISSION 0000899243-22-012990 24993
2022-03-31 4 FORM 4 SUBMISSION 0000899243-22-012989 7024
2022-03-31 4 FORM 4 SUBMISSION 0000899243-22-012988 22701
2022-03-31 4 OWNERSHIP DOCUMENT 0001104659-22-041080 22584
2022-03-29 S-8 S-8 0001193125-22-086928 333-263917 22776749 33 108802
2022-03-28 424B4 424B4 0001193125-22-085459 333-263295 22773008 33 3874230
2022-03-24 SEC STAFF LETTER filename1.pdf 9999999997-22-001197 274805
2022-03-24 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2022-03-24 16:00:00 9999999995-22-000716 333-263295 22768126 33 1687
2022-03-24 S-1MEF S-1MEF 0001193125-22-084274 333-263840 22768108 33 68319
2022-03-24 3 FORM 3 SUBMISSION 0000899243-22-012182 11829
2022-03-24 3 FORM 3 SUBMISSION 0000899243-22-012181 7894
2022-03-24 3 FORM 3 SUBMISSION 0000899243-22-012180 7860
2022-03-24 3 FORM 3 SUBMISSION 0000899243-22-012179 10075
2022-03-24 3 FORM 3 SUBMISSION 0000899243-22-012175 9671
2022-03-24 3 FORM 3 SUBMISSION 0000899243-22-012174 13032
2022-03-24 3 FORM 3 SUBMISSION 0000899243-22-012173 7968
2022-03-24 3 OWNERSHIP DOCUMENT 0001104659-22-037672 13421
2022-03-24 3 FORM 3 SUBMISSION 0000899243-22-012170 8622
2022-03-24 3 FORM 3 SUBMISSION 0000899243-22-012167 12754
2022-03-24 3 FORM 3 SUBMISSION 0000899243-22-012164 11837
2022-03-24 3 FORM 3 SUBMISSION 0000899243-22-012163 11087
2022-03-24 3 FORM 3 SUBMISSION 0000899243-22-012162 10632
2022-03-24 3 FORM 3 SUBMISSION 0000899243-22-012158 15225
2022-03-24 3 FORM 3 SUBMISSION 0000899243-22-012157 7856
2022-03-24 CERT 8A_Cert_ANTX.pdf 0001354457-22-000197 001-41331 22765238 34 215528
2022-03-22 8-A12B 8-A12B 0001193125-22-081697 001-41331 22760307 34 13327
2022-03-22 CORRESP filename1.htm 0001193125-22-081637 10590
2022-03-22 CORRESP filename1.htm 0001193125-22-081632 7849
2022-03-21 S-1/A S-1/A 0001193125-22-080012 333-263295 22754177 33 4957218
2022-03-10 SEC STAFF LETTER filename1.pdf 9999999997-22-000786 276091
2022-03-04 S-1 REGISTRATION STATEMENT ON FORM S-1 0001193125-22-066048 333-263295 22713992 33 6460394
2022-01-19 DRSLTR filename1.htm 0000950123-22-000334 32059
2022-01-19 DRS/A filename1.htm 0000950123-22-000333 377-05527 22539132 33 3835665
2021-12-03 UPLOAD filename1.pdf 0000000000-21-014591 48412
2021-11-19 DRS/A filename1.htm 0000950123-21-015729 377-05527 211426253 33 3600553
2021-11-18 DRSLTR filename1.htm 0000950123-21-015730 55090
2021-10-22 UPLOAD filename1.pdf 0000000000-21-012872 65781
2021-09-24 DRS filename1.htm 0000950123-21-012609 377-05527 211278120 33 4331253

Latest XBRL company facts

One latest value per concept from companyfacts (184 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 37.94M 2026-11-05 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
dei EntityPublicFloat Entity Public Float USD 23.08M 2025-06-30 2025 FY 10-K 2026-03-17 0001193125-26-110693
ffd NetFeeAmt NetFeeAmt USD 964.97 2026-09-14 S-8 2026-09-14 0001880438-26-000002
ffd TtlFeeAmt TtlFeeAmt USD 964.97 2026-09-14 S-8 2026-09-14 0001880438-26-000002
ffd TtlOfferingAmt TtlOfferingAmt USD 6.99M 2026-09-14 S-8 2026-09-14 0001880438-26-000002
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-04-09 S-3 2026-04-09 0001193125-26-149869
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-04-09 S-3 2026-04-09 0001193125-26-149869
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 1.66M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 377,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 2.13M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -207,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 342.84M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 973,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 8.10M 2022-01-01 2022-03-31 2023 Q1 10-Q 2023-05-11 0000950170-23-021291
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 3.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss USD 0 2023-09-30 2023 Q3 10-Q 2023-11-09 0000950170-23-062081
us-gaap AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) USD 1,000 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-10 0000950170-22-008999
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 7.86M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap Assets Assets USD 81.95M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap AssetsCurrent Assets, Current USD 65.76M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 0 2022-06-30 2022 Q2 10-Q 2022-08-11 0000950170-22-016900
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 44.19M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Debt Securities, Available-for-sale, Noncurrent USD 15.80M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap CapitalizedContractCostAmortization Capitalized Contract Cost, Amortization USD 0 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-09 0000950170-23-062081
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 20.21M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD 70.42M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-10 0000950170-22-008999
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 95.30M 2023-06-30 2023 Q2 10-Q 2023-08-10 0000950170-23-041378
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 20.21M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 266,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value USD 82.50M 2022-03-31 2022 Q1 10-Q 2022-05-10 0000950170-22-008999
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 0 2025-06-30 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 2.95M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 18.71M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 500.00M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 37.89M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 37.89M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -26.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 111.14M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-29 0000950170-24-038681
us-gaap DebtSecuritiesAvailableForSaleAccruedInterestWriteoff Debt Securities, Available-for-Sale, Accrued Interest Writeoff USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Debt Securities, Available-for-sale, Allowance for Credit Loss USD 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions Security 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap DebtSecuritiesAvailableForSaleUnrealizedGainLoss Debt Securities, Available-for-sale, Unrealized Gain (Loss) USD 300,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 0 2023-12-31 2023 FY 10-K 2024-03-29 0000950170-24-038681
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 5.34M 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010627
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 55.75M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 28.81M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 228,000 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 7.73M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 4.19M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 55.75M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010627
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.63 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -2.98 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-10 0000950170-22-008999
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.63 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.226 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure -0.002 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount USD 360,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent pure -0.007 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0.184 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.02 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 1.54M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 3.30M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap FairValueAssetsLevel1ToLevel2TransfersAmount Fair Value, Assets, Level 1 to Level 2 Transfers, Amount USD 0 2022-03-31 2022 Q1 10-Q 2022-05-10 0000950170-22-008999
us-gaap FairValueAssetsLevel2ToLevel1TransfersAmount Fair Value, Assets, Level 2 to Level 1 Transfers, Amount USD 0 2022-03-31 2022 Q1 10-Q 2022-05-10 0000950170-22-008999
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 9.64M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ImpairmentOfInvestments Other than Temporary Impairment Losses, Investments USD 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-14 0000950170-24-059556
us-gaap IncomeTaxesPaidNet Income Taxes Paid, Net USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 7.96M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -7.39M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap IncomeTaxReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount USD 84,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 360,000 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-25 0000950170-25-044366
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD -6.48M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 718,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -1.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD -2,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -53,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-25 0000950170-25-044366
us-gaap IncreaseDecreaseInOtherCurrentLiabilities Increase (Decrease) in Other Current Liabilities USD -284,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap IncreaseDecreaseInOtherNoncurrentLiabilities Increase (Decrease) in Other Noncurrent Liabilities USD 170,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap IncreaseDecreaseInOtherOperatingAssets Increase (Decrease) in Other Operating Assets USD 720,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010627
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -489,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 1.96M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap InvestmentIncomeNet Investment Income, Net USD 1.35M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010627
us-gaap Investments Investments USD 60.00M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap LeaseCost Lease, Cost USD 161,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0000950170-24-038681
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 54,000 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010627
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 54,000 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010627
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 20,000 2022-09-30 2022 Q3 10-Q 2022-11-09 0000950170-22-023901
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 1,000 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010627
us-gaap Liabilities Liabilities USD 6.45M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 81.95M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap LiabilitiesCurrent Liabilities, Current USD 6.28M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 45.25M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -19.81M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -25.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -26.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -26.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap OperatingExpenses Operating Expenses USD 28.13M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -28.13M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap OperatingLeaseCost Operating Lease, Cost USD 54,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0000950170-24-038681
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 50,000 2022-01-01 2023 FY 10-K 2024-03-29 0000950170-24-038681
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 53,000 2022-12-31 2023 FY 10-K 2024-03-29 0000950170-24-038681
us-gaap OperatingLeasePayments Operating Lease, Payments USD 50,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0000950170-24-038681
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 50,000 2022-01-01 2023 Q3 10-Q 2023-11-09 0000950170-23-062081
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.051 2022-12-31 2023 FY 10-K 2024-03-29 0000950170-24-038681
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 42,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 387,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -264,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD -184,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 945,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 170,000 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -1,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010627
us-gaap PaymentsForRestructuring Payments for Restructuring USD 2.20M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 1.21M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010627
us-gaap PaymentsToAcquireInvestments Payments to Acquire Investments USD 49.80M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap PreferredStockDividendsAndOtherAdjustments Preferred Stock Dividends and Other Adjustments USD 1.82M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-29 0000950170-24-038681
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 1.36M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 70.37M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-29 0000950170-24-038681
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 86,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Proceeds from Issuance of Redeemable Convertible Preferred Stock USD 79.73M 2021-01-01 2021-03-31 2022 Q1 10-Q 2022-05-10 0000950170-22-008999
us-gaap ProceedsFromSaleMaturityAndCollectionsOfInvestments Proceeds from Sale, Maturity and Collection of Investments USD 29.99M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Proceeds from Sale of Debt Securities, Available-for-sale USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 243,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 111,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -26.17M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap RelatedPartyCosts Related Party Costs USD 0 2023-01-01 2023-06-30 2023 Q2 10-Q 2023-08-10 0000950170-23-041378
us-gaap RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty Related Party Transaction, Expenses from Transactions with Related Party USD 500,000 2022-01-01 2022-06-30 2023 Q2 10-Q 2023-08-10 0000950170-23-041378
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 18.49M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent pure 0.5 2024-08-08 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap RestructuringCharges Restructuring Charges USD 2.23M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap RestructuringReserve Restructuring Reserve USD 500,000 2024-09-30 2024 Q3 10-Q 2024-11-13 0000950170-24-126282
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -267.12M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 3.40M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Payments USD 0 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277673
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 1.09 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.042 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 7.40M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 4.59M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 7.28 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 44,864 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 6.18 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 524,026 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0000950170-24-126282
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 1.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 1.58 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 14.19M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 6.56M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 5.74 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value USD 1.60M 2022-01-01 2022-06-30 2022 Q2 10-Q 2022-08-11 0000950170-22-016900
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost Share-based Payment Arrangement, Plan Modification, Incremental Cost USD 400,000 2026-03-19 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 2.26 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 8.78 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-13 0000950170-24-126282
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 1.86 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 107,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-29 0000950170-24-038681
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 75.51M 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 2.353 2022-03-17 2023 FY 10-K 2024-03-29 0000950170-24-038681
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 107,633 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 111.14M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-29 0000950170-24-038681
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 72,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 65.48M 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-25 0000950170-25-044366
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 165,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 109.32M 2021-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010627
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 103.06M 2021-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010627
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 11.41M 2021-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010627
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 11.41M 2021-12-31 2022 FY 10-K 2023-03-29 0000950170-23-010627
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 0 2023-12-31 2023 FY 10-K 2024-03-29 0000950170-24-038681
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 10.53M 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions USD 249,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 8.20M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD -2.40M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-17 0001193125-26-110693
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 41.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 3.18M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-10 0000950170-22-008999
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 41.69M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-09 0001193125-26-452664

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →